Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP612982.RAR3CChVjc0aNTIiR7OMjyXnZUP-AASLrUyMk8fabtfak130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP612982.RAR3CChVjc0aNTIiR7OMjyXnZUP-AASLrUyMk8fabtfak130_provenance.
• NP924759.RAeXNHYj-eChvIviO8IrC2PfxtW7c6ZfdJuAxoAsqba7k130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924759.RAeXNHYj-eChvIviO8IrC2PfxtW7c6ZfdJuAxoAsqba7k130_provenance.
• NP924813.RAXdbOukudWH4fiuh_46gLKvGigQaKlJNOUAJ6I7LLsEg130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924813.RAXdbOukudWH4fiuh_46gLKvGigQaKlJNOUAJ6I7LLsEg130_provenance.
• assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP586028.RADsiDMF7H0KvzRUq2M0lJBAel7GV8plv20vMkrsw_Ui8130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586028.RADsiDMF7H0KvzRUq2M0lJBAel7GV8plv20vMkrsw_Ui8130_provenance.
• NP586029.RAAXD2VdIfc85iy5DGGgtxNHMN3SXpSCmgQuH416wfdKE130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586029.RAAXD2VdIfc85iy5DGGgtxNHMN3SXpSCmgQuH416wfdKE130_provenance.
• NP586026.RAaBYDv1E3dsdaFUd6TuG6fr3NBvnl9PtS6H4-1oSQpbA130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586026.RAaBYDv1E3dsdaFUd6TuG6fr3NBvnl9PtS6H4-1oSQpbA130_provenance.
• NP612974.RAimE4yJl6u9T_AcbiDJ7o5C68wnwmjZP0m088g5OoRzA130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP612974.RAimE4yJl6u9T_AcbiDJ7o5C68wnwmjZP0m088g5OoRzA130_provenance.
• NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_provenance.
• NP586032.RAtEptzZxy4o5-nrfrLWl-iQ00jFHTfVP1QdCzPwc7Po8130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586032.RAtEptzZxy4o5-nrfrLWl-iQ00jFHTfVP1QdCzPwc7Po8130_provenance.
• NP612987.RAOPl3KAPAzVaqVOO_Mba3Su7i_3lzDta0kgNeGOV9YP8130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP612987.RAOPl3KAPAzVaqVOO_Mba3Su7i_3lzDta0kgNeGOV9YP8130_provenance.
• NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_provenance.
• NP924757.RAOJZU_e1r43nOSKOd-Km7syeZWeo_XMb7dK_tVNU65nY130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924757.RAOJZU_e1r43nOSKOd-Km7syeZWeo_XMb7dK_tVNU65nY130_provenance.
• NP924777.RA_GtZoC-xTntVTffaW3UGMrhVMtL1NHais6y6K4BY1Ew130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924777.RA_GtZoC-xTntVTffaW3UGMrhVMtL1NHais6y6K4BY1Ew130_provenance.
• NP586024.RA_e40IwoBHUOF69tLIbCnLAKCQgk2TsSg8EpqlYgHDbo130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586024.RA_e40IwoBHUOF69tLIbCnLAKCQgk2TsSg8EpqlYgHDbo130_provenance.
• NP586025.RA-Mp-wTsu4eP_rHkumk7gr6tLfn3N53qoGEYL1ZsUm0w130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586025.RA-Mp-wTsu4eP_rHkumk7gr6tLfn3N53qoGEYL1ZsUm0w130_provenance.
• NP586031.RA8Fi-nd-xWEKPgDKtoaA1y-eefkr308PdxLWBTwYYzxk130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586031.RA8Fi-nd-xWEKPgDKtoaA1y-eefkr308PdxLWBTwYYzxk130_provenance.